Show
Sort by
-
- Journal Article
- A1
- open access
Real-life effectiveness of mepolizumab in severe asthma : a systematic literature review
-
Personalized medicine for allergy treatment : allergen immunotherapy still a unique and unmatched model
-
- Journal Article
- A1
- open access
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020)
-
SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials
-
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps : a systematic review for the EAACI guidelines
-
COVID‐19 pandemic : practical considerations on the organization of an allergy clinic : an EAACI/ARIA position paper
-
- Journal Article
- A1
- open access
Eosinophilic and noneosinophilic asthma : an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort
-
- Journal Article
- A1
- open access
Association between a type 2 inflammatory disease burden score and outcomes among patients with asthma
-
3TR : a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD
-
- Journal Article
- A1
- open access
Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care
-
- Journal Article
- A1
- open access
International severe asthma registry (ISAR) : protocol for a global registry
-
- Journal Article
- A1
- open access
Beliefs and preferences regarding biological treatments for severe asthma
-
Dupilumab reduces severe outpatient asthma exacerbations, cumulative dose, and total number of days of systemic corticosteroid use among patients with moderate-to-severe type-2 asthma
-
- Journal Article
- A1
- open access
EUFOREA consensus on biologics for CRSwNP with or without asthma
-
Next-generation care pathways for allergic rhinitis and asthma multimorbidity : a model for multimorbid non-communicable diseases : meeting report (part 1)
-
Allergic Rhinitis and its Impact on Asthma (ARIA) phase 4 (2018) : change management in allergic rhinitis and asthma multimorbidity using mobile technology
-
2019 ARIA Care pathways for allergen immunotherapy
-
ARIApharmacy 2018 'Allergic rhinitis care pathways for community pharmacy'
-
Electronic clinical decision support system for allergic rhinitis management: MASK e-CDSS
-
- Journal Article
- A1
- open access
Validation of the Global Allergy and Asthma European Network (GA2LEN) chamber for trials in allergy : innovation of a mobile allergen exposure chamber